(News Bulletin 247) – In a note on European biotechnology stocks, Oddo BHF indicates that it favors Valneva, as well as Abivax and Genfit, with ‘outperformance’ opinions and price targets raised to 12, 30 and 8.8 respectively euros.
“These three titles benefit from solid shareholders accompanied by a clinical and regulatory newsflow whose risk/reward seems attractive to us over the next 18 months,” explains the analyst in charge of the file.
Oddo BHF points out that the stock market performance of the sector at the start of 2023 was once again extremely heterogeneous. “A rebound in M&A operations is finally materializing, which should reinvigorate an apathetic sector,” he points out, however.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
